NCT07029412Phase 2Completed

Study to Evaluate Efficacy and Dose Response of Imapextide (STEADI)

Study sponsor: MBX Biosciences

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-04-18Actual
Enrollment · participants20Actual
Source updated2026-07-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 10 participants (planned). After: 20 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: 22 Dec 2025. After: 18 Apr 2026.

Recruitment status changed

Before: Recruiting. After: Completed.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following 2 different dose levels of MBX 1416.. After: Measure: Changes from baseline to post-treatment in glucose nadir during a standardized MMTT following different dose levels of MBX 1416..

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview